WO2001009303A3 - Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER - Google Patents
Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER Download PDFInfo
- Publication number
- WO2001009303A3 WO2001009303A3 PCT/US2000/020679 US0020679W WO0109303A3 WO 2001009303 A3 WO2001009303 A3 WO 2001009303A3 US 0020679 W US0020679 W US 0020679W WO 0109303 A3 WO0109303 A3 WO 0109303A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- flt
- ligand
- encoding
- vertebrate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a pharmaceutical composition, comprising a first non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding a Flt-3 ligand, and a second non-infectious, non-integrating nucleic acid molecule construct comprising a polynucleotide encoding an antigen or a cytokine. The present invention also provides a method broadly directed to enhancing immune response of a vertebrate in need of immunotherapy which entails administering in vivo, into a tissue of a vertebrate, a Flt-3 ligand-encoding polynucleotide and one or more antigen- or cytokine-encoding polynucleotides. The polynucleotides are incorporated into the cells of the vertebrate in vivo, and a prophylactically or therapeutically effective amount of a Flt-3 ligand and one or more antigens is produced in vivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14617099P | 1999-07-30 | 1999-07-30 | |
US60/146,170 | 1999-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001009303A2 WO2001009303A2 (en) | 2001-02-08 |
WO2001009303A3 true WO2001009303A3 (en) | 2001-08-16 |
Family
ID=22516137
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/020679 WO2001009303A2 (en) | 1999-07-30 | 2000-07-31 | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2001009303A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
EP1278551A2 (en) | 2000-04-21 | 2003-01-29 | Vical Incorporated | Compositions and methods for (in vivo) delivery of polynucleotide-based therapeutics |
US20030017529A1 (en) * | 2001-06-27 | 2003-01-23 | Applera Corporation | Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
CA2480128A1 (en) * | 2002-03-26 | 2003-10-09 | Immunex Corporation | Methods of using flt3-ligand in immunization protocols |
CA2511927A1 (en) * | 2002-12-27 | 2004-08-12 | Shenzhen Tsinghua Yuanxing Bio-Pharm Science & Technology Co., Ltd. | Method of preparing a vaccine and anti-tumor vaccines |
US7504243B2 (en) | 2004-03-19 | 2009-03-17 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the production of biliverdin |
EP1877087B1 (en) | 2005-04-15 | 2013-02-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen |
EP3495000A1 (en) | 2009-02-17 | 2019-06-12 | Cornell Research Foundation, Inc. | Methods and kits for diagnosis of cancer and prediction of therapeutic value |
CA2782333C (en) | 2009-12-02 | 2019-06-04 | Imaginab, Inc. | J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use |
US9101557B2 (en) | 2011-04-13 | 2015-08-11 | Auburn University | Combination of protein forms for hornfly vaccination |
EP4137158A1 (en) | 2015-08-07 | 2023-02-22 | Imaginab, Inc. | Antigen binding constructs to target molecules |
AU2017363256B2 (en) * | 2016-11-22 | 2024-04-18 | Alloplex Biotherapeutics | Allogeneic tumor cell vaccine |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
CN110338153B (en) * | 2019-07-15 | 2021-08-03 | 杭州森康林业科技有限公司 | Pine wood nematode polypide fixing method for microinjection |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012633A1 (en) * | 1995-10-04 | 1997-04-10 | Immunex Corporation | Dendritic cell stimulatory factor |
WO1999026663A2 (en) * | 1997-11-20 | 1999-06-03 | Vical, Inc. | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
-
2000
- 2000-07-31 WO PCT/US2000/020679 patent/WO2001009303A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997012633A1 (en) * | 1995-10-04 | 1997-04-10 | Immunex Corporation | Dendritic cell stimulatory factor |
WO1999026663A2 (en) * | 1997-11-20 | 1999-06-03 | Vical, Inc. | Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor |
Non-Patent Citations (3)
Title |
---|
CHEN KEYUE ET AL: "Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model.", CANCER RESEARCH, vol. 57, no. 16, 1997, pages 3511 - 3516, XP002159231, ISSN: 0008-5472 * |
FERNANDEZ N ET AL: "ACTIVE SPECIFIC T-CELL-BASED IMMUNOTHERAPY FOR CANCER: NUCLEIC ACIDS, PEPTIDES, WHOLE NATIVE PROTEINS, RECOMBINANT VIRUSES, WITH DENDRITIC CELL ADJUVANTS OR WHOLE TUMOR CELL-BASED VACCINES. PRINCIPLES AND FUTURE PROSPECTS", CYTOKINES, CELLULAR AND MOLECULAR THERAPY,MARTIN DUNITZ PUBLISHERS, LONDON,GB, vol. 4, no. 1, March 1998 (1998-03-01), pages 53 - 65, XP000857807, ISSN: 1368-4736 * |
MCCLANAHAN TERRILL ET AL: "Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand.", BLOOD, vol. 88, no. 9, 1996, pages 3371 - 3382, XP000979439, ISSN: 0006-4971 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8940871B2 (en) | 2006-03-20 | 2015-01-27 | The Regents Of The University Of California | Engineered anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting |
US8940298B2 (en) | 2007-09-04 | 2015-01-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
US9527919B2 (en) | 2007-09-04 | 2016-12-27 | The Regents Of The University Of California | High affinity anti-prostate stem cell antigen (PSCA) antibodies for cancer targeting and detection |
Also Published As
Publication number | Publication date |
---|---|
WO2001009303A2 (en) | 2001-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001009303A3 (en) | Flt-3 LIGAND-ENCODING POLYNUCLEOTIDE AS A POLYNUCLEOTIDE-BASED VACCINE ENHANCER | |
WO2000062800A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
JP2003528155A5 (en) | ||
WO2000057917A3 (en) | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines | |
EP2325205A3 (en) | Crystals of whole antibodies and fragments thereof and methods for making and using them | |
WO2002034205A3 (en) | Using heat shock proteins to increase immune response | |
WO2004064759A3 (en) | Use of tryptanthrin compounds for immune potentiation | |
WO2001026681A3 (en) | Method of obtaining cellular immune responses from proteins | |
EP1659178A3 (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination | |
WO1998033527A3 (en) | Cancer immunotherapy with semi-allogeneic cells | |
WO2001095919A3 (en) | A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses | |
WO2005007673A3 (en) | Immunogenic peptides | |
DE69716240T2 (en) | NEW METHOD FOR VACCINATION AND VACCINE SUBSTANCES THAT CONTAIN AN EPITOP-CODING NUCLEIC ACID AND AN EPITOP-CONTAINING PEPTIDE | |
WO2001097841A3 (en) | Qs-21 and il-12 as an adjuvant combination | |
WO2002032378A3 (en) | Fusion cells and cytokine compositions for treatment of disease | |
ATE399022T1 (en) | COMPOSITION AND METHOD FOR ENHANCING THE IMMUNE RESPONSE OF ANTIGEN-PRESENTING CELLS | |
WO2003039592A3 (en) | Cellular vaccines comprising adjuvants | |
Osorio et al. | Immune responses to hepatitis B surface antigen following epidermal powder immunization | |
WO2003093298A3 (en) | Immunogenic peptides | |
WO2003051454A3 (en) | Methods for particle-assisted polynucleotide immunization using a pulsed electric field | |
WO2001056601A3 (en) | Low dose haptenized tumor cell and tumor cell extract immunotherapy | |
WO2002053176A3 (en) | An autologous anti-cancer vaccine | |
Maubant et al. | Adjuvant properties of cytosine-phosphate-guanosine oligodeoxynucleotide in combination with various polycations in an ovalbumin-vaccine model | |
EP1801123A3 (en) | Crystals of whole antibodies and fragments thereof and methods for making and using them | |
EP1905449A3 (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |